妊娠合并系统性红斑狼疮7例临床分析

目的:明确妊娠与系统性红斑狼疮(SLE)间的相互影响,探讨对妊娠合并高血压或蛋白尿患者中SLE的早期识别、诊断与治疗方法.方法:对近8年来我院7例妊娠合并SLE的高危患者进行回顾分析,观察其病情演变与治疗间的关系.结果:4例妊娠后初发SLE患者均伴有血压升高及尿蛋白阳性,其中3例患者病情危重(死亡1例),足月分娩1例,早产3例(死亡1例).3例妊娠前确诊患者,其中1例控制期患者合并有高血压;2例缓解期患者中1例合并有蛋白尿,但病情均平稳,3例均足月分娩,1例为小于胎龄儿.结论:妊娠可诱发或加重SLE.妊娠后初发的患者妊娠结局差,合并高血压及蛋白尿预后较差;SLE控制期和缓解期妊娠预后较好.应加强妊娠合并高血压或蛋白尿患者中SLE的早期识别、诊断及相应治疗.     

妊娠合并慢性骨髓增殖性疾病11例临床分析

目的 探对妊娠合并慢性骨髓增殖性疾病(CMPD)的临床特点及处理、妊娠结局及预后.方法 回顾性分析北京大学人民医院妇产科2000-2009年收治的11例妊娠合并CMPD患者[其中原发性血小板增多症(ET)5例,原发性骨髓纤维化(PMF)1例,慢性粒细胞白血病(CML)5例]的临床资料.结果 11例妊娠合并CMPD患者共妊娠12例次.(1)有规律产前检查者5例次,均行定期血常规等检查,适当给予抗凝治疗,预防并发症发生.其中1例PMF患者为孕前诊断,初次妊娠至32周时发生轻度子痫前期及胎死宫内;2年后再次妊娠,孕早期筛查抗β2糖蛋白Ⅰ抗体升高,给予小剂量阿司匹林口服及低分子肝素抗凝治疗,孕期顺利、足月分娩.(2)无规律产前检查者5例次,其中ET患者2例次,CML患者3例次.1例ET患者于妊娠25周发生重度子痫前期,脐动脉舒张期血流反向,经解痉、降压及抗凝治疗效果不佳,因血压进行性升高、胎盘早剥而紧急行剖官产术终止妊娠,胎儿娩出即死亡.从未产前检查者2例次,均因临产入院,诊断为CML.(3)合并羊水过少4例次,子痫前期3例次,其中重度子痫前期2例次,轻度子痫前期1例次,所有患者均无严重出血及血栓形成等并发症发生.(4)妊娠至足月者8例次,其中4例次剖宫产分娩;4例次阴道分娩.早产2例次,均因羊水进行性减少以剖宫产术终止妊娠.分娩的10例新生儿出生体质量1820～3600 g,除1例并发重度子痫前期者出现胎儿生长受限(FGR)外,其余均为适于胎龄儿.(5)11例患者妊娠期间原有疾病均病情稳定,其中3例CML患者妊娠晚期口服羟基脲治疗,4例ET患者及1例CML患者终止妊娠前进行血小板单采术治疗,效果良好.除1例CML患者分娩后5个月因疾病进展死亡外,余患者产后病情均平稳.结论 妊娠合并CMPD患者多数妊娠结局良好,孕期管理需警惕血栓形成、子痫前期、胎死官内、FGR等并发症.合理应用抗凝等治疗,有助改善母儿结局.     

超声诊断非瘢痕子宫妊娠破裂3例

目的分析妊娠合并梅毒感染孕产妇的临床特征及妊娠结局。方法对本院2016年1月至2019年7月诊治的52例妊娠合并梅毒感染孕产妇的临床资料进行回顾性分析。结果 52例妊娠合并梅毒感染患者中,38例孕产妇在产前检查时诊断,平均诊断孕周为(21.45±9.95)周;另14例为分娩时实验室检查发现。51例患者为潜伏梅毒,1例表现为二期梅毒。38例产前检查时确诊的梅毒患者中,32例接受了抗梅毒治疗。妊娠结局为终止妊娠2例、自然流产1例,死胎2例,早产6例,足月分娩41例。47例新生儿中,发生7天内死亡1例,先天梅毒2例。结论妊娠合并梅毒感染以潜伏梅毒为主,妊娠早期的梅毒筛查及规范的抗梅毒治疗可以阻断梅毒母婴传播,减少产妇不良妊娠结局的发生。     

妊娠合并艾森曼格综合征9例临床分析

目的:探讨妊娠合并艾森曼格综合征对妊娠结局的影响,及其治疗措施。方法:对1997年1月至2009年12月我院收治的9例妊娠合并艾森曼格综合征患者的临床资料进行回顾分析。结果:9例患者,不定期产前检查3例,定期产前检查6例;合并子痫前期4例(重度1例,轻度3例),合并肺部感染2例,合并妊娠期糖尿病1例,无合并症2例。产妇死亡3例,死亡率33.3%;围生儿共11例,死亡1例,死胎2例,总死亡率27.3%。结论:妊娠合并艾森曼格综合征母儿预后差(尤其是合并重症疾病),不宜妊娠,一旦妊娠应尽早行人工流产术。希望继续妊娠者,应定期产前检查,早住院监护治疗,加强与心内科、麻醉科及新生儿科联合,改善母儿预后。     

妊娠合并结核病预后不良四例报告

结核病是可以治愈的 ,妊娠期结核病只要尽早诊断和积极治疗 ,妊娠结局往往是良好的 ;相反若缺乏警惕 ,不能尽早诊断和有效治疗 ,妊娠结局难以预料。我们收集了近 15年来我院 4例妊娠合并肺结核病预后不良患者的临床资料 ,现结合文献总结如下。一、临床资料1.一般资料 :年龄 :2 5～ 38岁。职业 :农民 2例 ,护士、工人各 1例。孕产次 :3例初孕初产 ,1例孕 3产 2。产前检查次数 :3例 8次以上 ,1例 4次。分娩孕周 :3例足月产 ,1例早产。分娩方式 :3例阴道分娩 ,1例剖宫产。围产儿结局 :1例早产儿死亡 ,另 3例新生儿正常。2 .临床表现及诊断 :4例…     

妊娠合并艾森曼格综合征的治疗对策

目的 探讨对妊娠合并艾森曼格综合征患者的治疗时策,以期降低此类孕、产妇的病死率.方法 回顾性分析北京大学第一医院2002年1月至2006年12月期间收治的4例妊娠合并艾森曼格综合征患者.结果 4例患者年龄22～34岁,孕周34～35周.2例患者未定期孕期检查,外院急诊转入,1例临产急诊入院后1h余阴道分娩.分娩后突然死亡;另外1例行剖宫产术.其余2例为定期产前保健者,孕晚期入院监护治疗,给予吸氧、卧床体息、严密监测生命体征、血液动力学、血气的变化及胎儿发育情况,择期行剖宫产术.3例行剖宫产者产科与心内科、麻醉科医师密切合作,评估患者的心功能并动态观察,产后恢复良好.结论 妊娠合并艾森曼格综合征母儿预后很差,不宜妊娠,一旦妊娠应尽早行人流术终止妊娠.如果患者坚决要求继续妊娠,应加强产前保健尽早住院监护,加强与心内科、麻醉科、新生儿科合作,全面、正确、有效的处理有助于使患者平稳渡过围生期,改善母儿的预后.     

妊娠合并恶性肿瘤14例临床分析

目的探讨妊娠合并恶性肿瘤患者的临床特点及母儿结局。 方法收集2009年10月至2015年12月就诊于广州医科大学附属第三医院妇产科的14例妊娠合并恶性肿瘤患者的临床资料,对患者的临床特点、孕期治疗、妊娠结局及预后进行分析。 结果14例妊娠合并恶性肿瘤患者的肿瘤类型分别为血液系统恶性肿瘤(8例)、乳腺癌(4例)和宫颈癌(2例)。足月分娩者有5例,早产6例,1例早期人工流产,1例中孕期引产,1例孕期死亡。共分娩新生儿11例,2例乳腺癌患者于孕期接受抗癌治疗,2例新生儿为足月儿;10例患者孕期选择期待治疗,9例患者的新生儿存活,包括3例足月儿和6例早产儿。 结论妊娠合并恶性肿瘤可导致严重的不良妊娠结局,根据病情孕期应进行合理的抗癌治疗可改善患者结局。     

妊娠合并急性胰腺炎19例回顾性分析

目的探讨妊娠合并急性胰腺炎的临床特征和治疗策略。方法回顾性分析2007年11月至2010年11月上海市第六人民医院妇产科收治的19例妊娠合并急性胰腺炎的临床资料,包括患者的临床表现、高危因素、诊断、治疗及预后。结果 19例患者中,轻型急性胰腺炎11例(57.9%),重型急性胰腺炎8例(42.1%)。致病危险因素主要为胆囊和(或)胆管结石(4例)及高脂血症(4例)。19例(100%)突发上腹疼痛,18例(94.5%)伴恶心呕吐。4例(21.1%)发热,8例(42.1%)全腹痛、腹胀,8例(42.1%)呼吸循环功能不稳定均预示重症急性胰腺炎存在。18例(94.5%)患者血和(或)尿淀粉酶水平升高;5例(26.3%)彩超诊断,8例(42.1%)彩超后行MRI或CT确诊。1例延误诊断。采用保守治疗15例(78.9%)效果较满意;4例(21.1%)外科干预。对重症患者,5例(26.3%)ICU监护,2例(10.5%)外科重症监护病房观察。19例(100%)患者预后好,无孕产妇死亡,早产7例(36.8%);围生儿死亡2例(10.5%)。结论妊娠期急性胰腺炎早期诊断及病情严重性评估非常重要;综合保守治疗效果较满意,重症患者加强监护,尽量延迟外科干预。     

妊娠合并恶性肿瘤15例临床分析

目的:探讨妊娠合并恶性肿瘤的临床特征及对母婴的影响,以利于早发现、早诊断、早治疗.方法:回顾性分析我院2007年7月至2011年1月妊娠合并恶性肿瘤15例患者的临床资料.结果:妊娠期最常见的恶性肿瘤为白血病(4例)、宫颈癌(2例).15例中死亡1例,未分娩1例,妊娠早期化疗后行人工流产5例,妊娠中期行依沙吖啶引产2例,...     

体外受精-胚胎移植术后宫内合并宫外妊娠5例临床分析

目的探讨体外受精-胚胎移植（IVF-ET）术后宫内合并宫外妊娠的发病因素和临床特征。方法对2009年1月至2014年4月IVF-ET术后5例宫内合并宫外妊娠患者的受孕方式、临床症状、辅助检查、治疗方法及妊娠结局进行回顾性分析。结果 5例患者中,IVF-ET术后第12~14天测尿或血β-hCG及阴道超声确定宫内合并宫外妊娠,其中腹痛4例,阴道出血4例,晕厥、休克1例。1例合并宫角妊娠,4例合并输卵管妊娠。输卵管切除5例,部分宫角切除1例。术后阴道出血或腹痛明显改善后定期产前检查,现2例已足月分娩,2例继续妊娠中,1例术后第1天宫内妊娠自然流产。结论 B超检查可及早发现宫内合并宫外妊娠,手术为其首选,早诊断、早治疗患者预后良好。     

12例子宫恶性肿瘤合并子宫内膜异位症临床病理特征分析

目的 总结子宫恶性肿瘤合并子宫内膜异位症患者的临床病理特征,并探讨两者的相互关系。方法 回顾性对北京大学人民医院1991年1月～2000年12月住院治疗的子宫恶性肿瘤合并子宫内膜异位症患者的临床病理资料进行分析。结果 188例子宫恶性肿瘤患者中合并子宫内膜异位症12例(6.38％),平均年龄50.67岁。常见的临床症状为阴道不规则出血或阴道排液。全部患者经手术治疗,术后病理证实合并内异症的子宫恶性肿瘤恶性程度较低(8例内膜癌均为I期,4例内膜间质肉瘤均为低度恶性)。异位病灶部位:卵巢9例,宫颈1例,淋巴结1例,骶骨韧带1例,其中合并子宫腺肌症2例。10例异位内膜表现不同程度的非典型增生(5例轻度,4例中重度,1例可见轻到中、重度的改变,最后发展成为间质肉瘤)。2例失访,1例死亡,余9例平均随访37个月,均存活。结论合并内异症的子宫恶性肿瘤疾病分期早,患者无瘤生存期长。临床工作中应仔细观察异位病灶的增生情况,对重度非典型增生患者进行全面检查和长期严密随访。     

妊娠合并妇科恶性肿瘤分娩时机及分娩方式的选择

宫颈癌和卵巢癌是妊娠期最常见的妇科恶性肿瘤,近年来随着生育年龄的推迟及促排卵药物的应用,妊娠合并妇科恶性肿瘤的发生率呈上升的趋势。既往在诊断恶性肿瘤后立即终止妊娠,而目前决定治疗方案时会充分考虑母体和胎儿二者的预后,从而将母胎死亡率和并发症降到最低。妊娠合并妇科恶性肿瘤分娩时机与分娩方式的选择没有统一的指南。文章结合相关文献,阐述妊娠合并宫颈癌、卵巢肿瘤、外阴癌的分娩时机与分娩方式,以供临床参考。     

Increased expression level of squamous cell carcinoma antigen 2 and 1 ratio is associated with poor prognosis in early-stage uterine cervical cancer

Squamous cell carcinoma antigen (SCCA) is a tumor marker for patients with squamous cell carcinoma of uterine cervix, lung, and esophagus. It was encoded by two highly homologous genes, SCCA1 and SCCA2. However, the relevance of SCCA genes to squamous cell carcinogenesis and patient outcome remains far from clear. In this study, by using laser microdissection and real-time quantitative polymerase chain reaction procedures, the messenger RNA (mRNA) expression of the SCCA1 and SCCA2 genes in normal, dysplastic, and malignant squamous epithelia from uterine cervical tissues were analyzed and correlated with outcome of cancer patients. We found that the SCCA2/A1 mRNA ratios were progressively increased from normal, dysplastic, to cancer cells, and the mean ratio was significantly higher in cancer tissues than that in normal epithelium (P= 0.02). The SCCA2/A1 mRNA ratios were not significantly associated with types of human papillomavirus infection (P > 0.05). High SCCA2/SCCA1 mRNA ratios (ratio >1) were an independent predictor of disease recurrence (relative risk: 3.58; P= 0.003). Of the 38 patients with cervical cancer, 12 patients with high SCCA2/SCCA1 mRNA ratios had a significant lower 2-year disease-free survival of only 50%, while it was 92% in those with low SCCA2/SCCA1 mRNA ratios (P < 0.001). In conclusion, our study indicated that the ratios of SCCA2 to SCCA1 RNA were increased during the process of cervical carcinogenesis, and patients with elevated SCCA2/A1 ratio carried a higher risk for recurrence in early-stage uterine cervical cancer.     

老年妇科恶性肿瘤160例临床分析

目的 :探讨老年妇科恶性肿瘤的临床特点及防治经验 ,提出有效保健措施。方法 :回顾分析 16 0例老年妇科恶性肿瘤的病历资料。结果 :6 4例宫体癌居首位 ,其次是卵巢癌 6 2例 ,12例宫颈癌为第 3位。 16 0例中 88例 (5 5 % )以阴道出血为主诉就诊 ,90例(5 6 .2 5 % )有内外科合并症。术前合并内外科疾病的肿瘤患者发生术后并发症例数与无合并症者发生的例数之间差异有高度显著性 (P <0 .0 1)。结论 :子宫内膜癌发病率有上升趋势 ;阴道超声及宫腔细胞学联合检查是较好的筛查内膜癌及癌前病变的方法 ;对老年患者术前应积极治疗合并症 ,加强围手术期的处理 ,减少并发症的发生。只要处理得当、在严密监护下老年人几乎可以耐受各种妇科手术。加强妇女保健、开展普查普治是降低妇科恶性肿瘤发病率 ,提高治愈率的有效措施     

Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor

OBJECTIVE: In the present study, the significance of circulating matrix metalloproteinases -2 and -9 (MMP-2, MMP-9), as well as their tissue inhibitors -1 and -2 (TIMP-1, TIMP-2) in ovarian cancer were studied to assess the possibility of using them in clinical decision-making. METHODS: We measured, prior to primary surgery, the concentrations of these proteins in serum samples of 115 patients with an ovarian tumor: 63 with cancer, 6 with a low malignant potential tumor, and 46 with a benign tumor. The measurements were performed with enzyme-linked immunosorbent assays (ELISA). The results were compared to clinicopathological data. RESULTS: A high serum concentration of TIMP-1 at diagnosis was found to correlate with the malignant phenotype of an ovarian tumor. Within malignant neoplasias, high circulating TIMP-1 correlated to the aggressive phenotype and unfavorable prognosis. An association was found between a high serum level of TIMP-1 and an advanced stage of the disease, a residual tumor>2 cm, poor response to cytotoxic treatment, shorter recurrence free time, and shorter cancer-related overall survival. No statistically significant correlation was found between the circulating gelatinases (MMP-2, MMP-9) or TIMP-2 and the clinicopathological factors. However, a tendency for better survival with high serum concentration of TIMP-2 or MMP-2 was observed. CONCLUSION: We conclude that an elevated preoperative serum TIMP-1 concentration correlates to the aggressive behavior of ovarian cancer.     

Neoadjuvant chemotherapy followed by radical hysterectomy for invasive cervical cancer diagnosed during pregnancy: report of a case and review of the literature

Although cervical carcinoma is among the most frequently encountered malignancies during pregnancy, only four cases of neoadjuvant chemotherapy during pregnancy have been reported. A 28-year-old A0P1G2M0 was diagnosed at 15 weeks with stage Ib1 invasive squamous cervical cancer. Because she strongly desired the continuation of this pregnancy, after extensive counseling she was treated with 75 mg/m(2) cisplatin every 10 days starting at 17 weeks. After six cycles, clinically and radiologically stable disease with normalization of the squamous cell carcinoma tumor marker was obtained. An elective cesarean delivery followed by radical hysterectomy and lymphadenectomy was performed at 32 weeks gestation. The pathology report revealed a moderately differentiated squamous cell carcinoma of 3.5 cm, and all 33 lymph nodes were free of disease. Neonatal examination of the baby could not reveal any abnormalities, and this was confirmed at 6 months. The use of neoadjuvant chemotherapy enabled us to continue this pregnancy until the fetus was viable. Cisplatin did not influence the short-term outcome, but only a long-term follow-up will inform us on its safety during pregnancy.     

Clinical analysis of patients with Krukenberg tumor of the ovary

OBJECTIVE: The aim of this study was to analyze clinical data such as diagnosis, surgical treatment and follow-up of patients with Krukenberg tumor (KT). We also reviewed literature of the subject. MATERIAL AND METHODS: We retrospectively analyzes medical data of 34 patients who were operated in Gynecology Clinic of Medical University of Gdansk in years 1999-2003. The definition of KT was that of Krukenberg's. RESULTS: The mean age of patients was 52, 23 of them were postmenopausal. Fourteen patients were diagnosed with malignant disease before surgery for ovarian tumor--11 were treated for breast cancer, 2 underwent resection of the stomach and one had rectosigmoidectomy. Before surgery a diagnosis for ovarian tumor such as ultrasonography, computer tomography and Ca125 were performed--in most cases sonography findings revealed mixed cystic and solid tumor of 320 cm in diameter; in 70% cases serum Ca125 was elevated with the highest result of 772 IU/ml. From among 20 patients who were suspected for primary ovarian cancer with no other malignant disease before surgery 9 had stomach cancer, 6 colon cancer, in 2 cases ovarian tumor was a metastasis from breast and in 1 from gall bladder; in 2 patients primary tumor was not found. The surgery performed in patients with KT was that of done for primary ovarian cancer. In 5 cased partial resection of colon was necessary. Surgical findings revealed ovarian tumor of 3-10 cm in diameter, solid and bilateral in most cases. The mean survival in our group was 4,7 months. The mean time between diagnosis of malignant disease and metastases to the ovary was 18 months. The best overall prognosis was for patients with breast cancer and the worst for cases with stomach cancer. CONCLUSIONS: There is a poor prognosis for patients with Krukenberg tumor. The diagnosis is late, in most cases during surgery for ovarian tumor. The most often site of primary malignancy was breast and stomach.     

Serum levels of six tumor markers in patients with benign and malignant gynecological disease

Summary We studied the pretreatment serum levels of 6 tumor markers in gynecological patients with and without malignant disease. The tumor markers were carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), ferritin, Schwangerschaftsprotein 1 (SP₁), Schwangerschaftsprotein 3 (SP₃) and cancer antigen 125 (CA125). The results were as follows: (1) Serum CA125 and TPA levels were raised in 81% and 57% of patients with ovarian serous cystadenocarcinoma: CEA and SP₃, in 52% and 43% respectively of patients with ovarian mucinous cystadenocarcinoma; CA125, TPA and SP₃, in 76%, 48% and 48% respectively of patients with other ovarian malignancies; and TPA and SP₃, in 56% and 40% respectively of patients with endometrial carcinoma. (2) Serum levels of TPA, ferritin and CA125 were more often raised with advancing stages of malignant disease. (3) Serum TPA levels were elevated in 55% of patients with stage I endometrial carcinoma, and serum SP₃ levels were elevated in 35% of patients with a stage I malignant ovarian neoplasm and in 45% of patients with endometrial carcinoma. (4) One of the 6 tumor markers showed a raised level in 84% of patients with gynecologic malignancy as against 56% in those with benign gynecologic diseases.     

Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer

OBJECTIVE: Matrix metalloproteinases (MMPs) are frequently expressed in malignant tumors and play an important role in tumor invasion and metastasis. MMP-2 and MMP-9 expression has been correlated with poor survival in some tumors, but data for ovarian cancer are lacking, despite clinical trials with MMP inhibitors. The aim of this study was to assess activity of MMP-2 and MMP-9 and correlate it to prognosis in ovarian cancer. METHODS: MMP-2 and MMP-9 gelatinolytic activity was analyzed in 84 patients with advanced ovarian cancer FIGO stage III and 19 benign ovarian tumors by gelatin zymography. MMP-9 immunoreactivity was detected by immunohistochemistry and gelatinolytic activity was localized in ovarian cancer tissue by in situ zymography. RESULTS: were correlated with patient survival, with a median follow-up period of 55 months. Results. Median pro-MMP-9 activity was at 0.00 U/microg protein in benign ovarian tissues and 4.82 U/microg protein in ovarian cancer (P = 0.001); activated MMP-9 was not detected. Pro-MMP-2 expression in benign ovarian tissue did not differ from that of malignant ovarian tissue, whereas active MMP-2 was present in 52% of ovarian cancers, but absent in benign ovarian tissues. Analyzing all patients high pro-MMP-9 activity was associated with short overall survival (P = 0.019) while pro-MMP-2 and activated MMP-2 did not predict overall survival. When analyzing the subgroups of patients with and without residual tumor mass at the time of surgery, pro-MMP-9 was of prognostic value only in the subgroup of patients with no residual tumor mass. In univariate analysis pro-MMP-9 activity, residual tumor mass, age, ascites volume, and grading were of prognostic significance for overall survival. However, in multivariate analyses, including all biological and clinicopathologic variables, only pro-MMP-9 and residual disease remained statistically independent prognostic factors. In situ zymography localized gelatinolytic activity predominantly to the tumor cell nests displaying MMP-9 immunoreactivity. CONCLUSIONS: Pro-MMP-9 gelatinolytic activity, but not active MMP-2 or MMP-9, serves as a useful statistically independent prognostic factor in ovarian cancer FIGO stage III, thus helping to identify ovarian cancer patients with an aggressive form of the disease.     

Ovarian carcinoma associated with pregnancy. A review of 9 cases

BACKGROUND: The purpose of this study was to review patients with ovarian cancer in pregnancy, the effectiveness of the available methods of treatment and their prognosis. METHODS: A retrospective review of all women diagnosed to have cancer of the ovary associated with pregnancy who delivered at the authors' hospitals between January 1976 and December 2000. The demography, clinical presentation, time and mode of diagnosis, treatment, pregnancy outcome and maternal survival were noted. RESULTS: The incidence of ovarian carcinoma in pregnancy in the series was 0.08/1000 deliveries. Of the 9 patients, 7 had epithelial cancers; 4 serous cystadenocarcinoma, 2 mucinous cystadenocarcinomas and one undifferentiated cancer. One patient each had dysgerminoma and granulosa cell tumor. Six patients were in FIGO stage Ia, one Ic, one IIa. One patient was in stage III. Five patients were treated by unilateral salpingo-oophorectomy during pregnancy. Three patients had total abdominal hysterectomy, bilateral salpingo-oophorectomy and omentectomy followed by chemotherapy. Debulking of the tumor was done in a patient in stage III with subsequent chemotherapy. This patient died 13 months from the time of diagnosis of the tumor. The overall 5-year survival rate in the series was 78% and 100% for stage Ia. CONCLUSIONS: Association of ovarian cancer with pregnancy is a rare occurrence. Early diagnosis and appropriate treatment offers the best prognosis for the patient. The higher survival rates in the series was attributed to a larger number of patients in stage I of the disease and 2 patients with a germ cell tumor and dysgerminoma which have the best prognosis. Aggressive postoperative chemotherapy also contributed to the better outcome.